Cover Image
市場調查報告書

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症) :開發中產品分析

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361618
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症) :開發中產品分析 Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 55 Pages
簡介

本報告提供次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):企業開發中的治療藥

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):大學/機關研究中的治療藥

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):企業開發中的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):大學/機關研究中的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症)的治療藥開發企業

  • Forendo Pharma Limited
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Repros Therapeutics Inc.

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):最近的開發平台趨勢

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):暫停中的計劃

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):開發中止的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9353IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Secondary (Hypogonadotropic) Hypogonadism - Overview
    • Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
    • Merck & Co Inc
    • Mereo Biopharma Group Plc
    • Repros Therapeutics Inc
  • Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
    • BGS-649 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corifollitropin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enclomiphene citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IAS-167A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kisspeptin-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSS-722 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
  • Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
  • Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
    • Featured News & Press Releases
      • Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
      • Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
      • Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
      • Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
      • Aug 15, 2016: Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
      • Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
      • Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
      • Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
      • Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
      • Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company
      • Jan 04, 2016: Repros Updates Enclomiphene Program
      • Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene
      • Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism
      • Jun 08, 2015: Repros Announces Date of FDA Advisory Committee Review of NDA
      • Apr 15, 2015: Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, H1 2017
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2017
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc, H1 2017
  • Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H1 2017
  • Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top